| abstract |
The present invention provides a NR2B subtype selective N-methyl-D-aspartate (NMDA) receptor antagonist to patients in need of treatment for traumatic brain injury (TBI), ischemic attack or hypoxic attack, (a) sodium channel antagonist. (b) nitric oxide synthase (NOS) inhibitors, (c) glycine site antagonists, (d) potassium channel openers, (e) AMPA (2-amino-3- (methyl-3-hydroxyisoxazole-4) -Yl) propanoic acid) / kainate receptor antagonists, (f) calcium channel antagonists, (g) gammaaminobutyric acid (GABA) -A receptor modulators (e.g. GABA-A receptor agonists) or (h) The present invention relates to a method of treating the above diseases, including administration in combination with an anti-inflammatory agent. The present invention also relates to a method for treating hypoxic or ischemic attack, comprising administering an NMDA receptor antagonist in combination with a thrombolytic agent to a patient in need of treatment for a hypoxic or ischemic attack. |